Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all blog posts
3.3.2011

Glaxo to Settle Avandia Cases with $250 Million

By Ji Sook Yim, Editor
In The News

GlaxoSmithKline GSK Glaxo buildingGlaxoSmithKline Plc agreed to pay over $250 million to settle 5,500 cases of reported deaths and injuries from its diabetes drug, Avandia.

The average settlement cost per plaintiff comes to around $46,000, but it would have been closer to $1 million if the evidence were strong enough to prove that heart attacks were definitely caused by Avandia.

Glaxo was supposed to go on its very first trial last week over claims that the drug killed one of its users. By fishing out $250 million, Glaxo conveniently avoids potentially exposing the drug’s deadly consequences.

Plaintiffs allege that before the settlement, Glaxo hid Avandia’s serious health risks, such as heart attacks and stroke, from doctors and patients. The drugmaker has faced these allegations by agreeing to pay $460 million.

 

In an attempt to make more amends, Glaxo is also issuing a new drug label, which now warns that Avandia is only intended for diabetic patients already using the drug, or for patients who can’t control their blood sugar with other diabetes medication.

This new label really narrows down the number of people who are allowed to take Avandia. In fact, the reported numbers for Avandia patients has plummeted from 600,000 to a current number of 100,000. And if you think of it, those numbers paint quite a disturbing picture: only 5,500 cases have been settled, yet nearly 500,000 people who previously took Avandia were at risk if they took it.

Kudos to Glaxo for settling these cases and issuing appropriate warnings.  But why wait so long to do it?  Cynics might say it  was to squeeze every last dime out of the drug in its original iteration before finally relenting and doing the right thing- but are they cynics or realists?

Sources:

Glaxo Said to Pay $250 Million to Resolve Avandia Suits
Avandia Gets Tougher Label, As Glaxo Reportedly Settles Lawsuits
Photo Credit: Ian Wilson

Share

No Comments

Leave a Reply Cancel reply

Receive News Updates

Get the latest from Wexler Wallace LLP & stay informed.

Categories

  • Media Appearances
  • Uncategorized
  • Columns
    • Guest Post
    • Ken Wexler
    • Ed Wallace
  • Practice Areas
    • Consumer Protection
    • Mass Tort Litigation
    • Business & Commercial Litigation
    • Healthcare Litigation
    • Employment Litigation
  • Cases
  • Hall Of Shame
    • Villain Of The Week
  • In The News
    • Public Victories
  • Featured Investigations
  • The Firm
    • News releases
    • Around The World
    • Our Professionals
    • Chicago
  • You Should Know
    • For Investors
    • For Businesses
    • For Consumers
  • Featured Cases
  • awards
  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP